ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
View original post here:
Supernus Announces First Quarter 2024 Financial Results
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024.
Read more here:
Cytek Biosciences Reports First Quarter 2024 Financial Results
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76
Follow this link:
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress.
Read this article:
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Read this article:
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial -
See the rest here:
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -
Continued here:
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY.
Read more from the original source:
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
See the rest here:
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update